Exhibit 8

Dr. Reddy’s Laboratories Limited

Subsidiary companies

As of March 31, 2012

Name of the subsidiary	Country of Incorporation	Percentage  of Direct/ Indirect Ownership Interest
Aurigene Discovery Technologies (Malaysia) SDN BHD	Malaysia		100	%(3)
Aurigene Discovery Technologies Inc.	USA		100	%(3)
Aurigene Discovery Technologies Limited	India		100	%
beta Healthcare Solutions GmbH	Germany		100	%(8)
beta Institut for Soziaimedizinische Forschung and Entwicklung GmbH	Germany		100	%(8)
betapharm Arzneimittel GmbH	Germany		100	%(8)
Cheminor Investments Limited	India		100	%
Chirotech Technology Limited	United Kingdom		100	%(5)
Dr. Reddy’s Bio-Sciences Limited	India		100	%
Dr. Reddy’s Farmaceutica Do Brasil Ltda.	Brazil		100	%
Dr. Reddy’s Laboratories (Australia) Pty. Limited	Australia		100	%
Dr. Reddy’s Laboratories (Canada) Inc.	Canada		100	%(10)
Dr. Reddy’s Laboratories (EU) Limited	United Kingdom		100	%(10)
Dr. Reddy’s Laboratories ILAC TICARET Limited SIRKETI	Turkey		100	%
Dr. Reddy’s Laboratories Inc.	USA		100	%(10)
Dr. Reddy’s Laboratories International SA	Switzerland		100	%(10)
Dr. Reddy’s Laboratories LLC, Ukraine	Ukraine		100	%(10)
Dr. Reddy’s Laboratories Louisiana LLC	USA		100	%(6)
Dr. Reddy’s Laboratories New York, Inc.	USA		100	%(13)
Dr. Reddy’s Laboratories (Proprietary) Limited	South Africa		100	%
Dr. Reddy’s Laboratories Romania SRL	Romania		100	%(10)
Dr. Reddy’s Laboratories SA	Switzerland		100	%
Dr. Reddy’s Laboratories Tennessee, LLC	USA		100	%(6)
Dr. Reddy’s Laboratories (UK) Limited	United Kingdom		100	%(5)
Dr. Reddy’s New Zealand Ltd. (formerly Affordable Healthcare Ltd.)	New Zealand		100	%(10)
Dr. Reddy’s Pharma SEZ Limited	India		100	%
Dr. Reddy’s SRL (formerly Jet Generici SRL )	Italy		100	%(11)
Dr. Reddy’s Venezuela, C.A.	Venezuela		100	%(10)
DRL Investments Limited	India		100	%
Eurobridge Consulting BV	Netherlands		100	%(1)
Industrias Quimicas Falcon de Mexico, S.A. deCV	Mexico		100	%
Idea2Enterprises (India) Pvt. Limited	India		100	%
I-Ven Pharma Capital Limited	India		100	%(12)
Kunshan Rotam Reddy Pharmaceutical Co. Limited (JV)	China		51.33	%(4)
Lacock Holdings Limited	Cyprus		100	%
OOO Dr. Reddy’s Laboratories Limited	Russia		100	%
OOO DRS LLC	Russia		100	%(9)
OOO Alfa (formerly OOO JV Reddy Biomed Limited)	Russia		100	%
Promius Pharma LLC (formerly Reddy Pharmaceuticals LLC)	USA		100	%(6)
Reddy Antilles N.V.	Netherlands		100	%
Reddy Cheminor S.A.	France		100	%(2)
Reddy Holding GmbH	Germany		100	%(7)
Reddy Netherlands B.V.	Netherlands		100	%(1)
Reddy Pharma Iberia SA	Spain		100	%
Reddy Pharma Italia SPA	Italy		100	%(7)
Reddy Pharmaceuticals Hongkong Limited	Hongkong		100	%(2)
Reddy US Therapeutics Inc.	USA		100	%(1)
Trigenesis Therapeutics Inc.	USA		100	%

(1) Indirectly owned through Reddy Antilles N.V.

(2) Subsidiary under liquidation.

(3) Indirectly owned through Aurigene Discovery Technologies Limited.

(4) Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary, as we hold a 51.33% stake. However, we account for this investment by the equity method and do not consolidate it in our financial statements.

(5) Indirectly owned through Dr. Reddy’s Laboratories (EU) Limited.

(6) Indirectly owned through Dr. Reddy’s Laboratories, Inc.

(7) Indirectly owned through Lacock Holdings Limited.

(8) Indirectly owned through Reddy Holding GmbH.

(9) Indirectly owned through Eurobridge Consulting B.V.

(10) Indirectly owned through Dr. Reddy’s Laboratories SA.

(11) Indirectly owned through Reddy Pharma Italia SPA.

(12) Indirectly owned through DRL Investments Limited

(13) Indirectly owned through Dr. Reddy’s Laboratories International SA.

Macred India Private Limited, India was our wholly-owned subsidiary until July 19, 2010, at which time we sold an 80% controlling interest in the entity and retained a 20% non-controlling interest. We sold our remaining 20% interest on February 24, 2012.

2